CSIR Central

Dihydrofolate reductase as therapeutics target for infectious diseases: opportunities and challenges

IR@CDRI: CSIR-Central Drug Research Institute, Lucknow


Field	Value

Creator	Sharma, Moni Chauhan, P M S

Date	2012-09-11T11:11:06Z 2012-09-11T11:11:06Z 2012

Identifier	Future Medicinal Chemistry 2012, 4(10), 1335-65 http://hdl.handle.net/123456789/917

Description	Infectious disease caused by parasites continues to take a massive toll on human health in the poor regions of the world. Filling the antiinfective drug discovery pipeline has never been as challenging as it is now. The organisms responsible for these diseases have an interesting biology, and many potential biochemical targets are now apparent. Inhibition of metabolic enzymes has been established an attractive strategy for the anti-infectious drug development. In this area, the Dihydrofolate reductase (DHFR) is an important enzyme in nucleic acid and amino acid synthesis in all cells and an extensively known drug target for over 50 year. The challenges for novel DHFR inhibition based chemotherapeutics for the treatment of infectious diseases are now in great demand due to overcoming resistance as well as cost effectiveness. Therefore, development of safe and selective DHFR inhibitors for the treating of infectious disease has promoted us to continue research in this area. Each year, the large number of literature citations attest to the continued popularity of DHFR. It is truly an “enzyme for all seasons.” Therefore, Herein, we summarize the opportunities and challenges in developing novel lead based on this target.

Format	930601 bytes application/pdf

Language	en

Relation	CDRI Communication No. 8224

Subject	Antiinfective Dihydrofolate reductase inhibitors Thymineless death Antibacterial Antiprotozoal Drug resistance 2,4 diaminopyrimidine

Title	Dihydrofolate reductase as therapeutics target for infectious diseases: opportunities and challenges

Type	Article